Category Archives: Stem Cell Research

BOSTON, June 17, 2021 /PRNewswire/ -- Next week, June 21-26, stem cell biotechnology company Asymmetrex will participate as a presenter and an exhibitor in the 2021 Annual Meeting of the International Society for Stem Cell Research. In an invited poster presentation (#345) and a company exhibitor display, Asymmetrex will introduce the virtual gathering of international stem cell scientists, physicians, and biotechnologists to its new technology for evaluating the potency of therapeutic tissue stem cells.

Potency tests assure doctors that a medicine has good quality and will be effective for treatment. Although potency tests are common for drug medicines, developing them for stem cell treatments has been difficult. For stem cell treatments, no reliable potency tests have been available.

At the June 21-26, 2021 Annual Meeting of the International Society for Stem Cell Research, stem cell biotechnology company Asymmetrex will present data and examples for a new test for evaluation of the potency of tissue stem cell treatments. The technology, called kinetic stem cell (KSC) counting, can tell doctors the number of live tissue-renewing stem cells in a treatment sample.

The President & CEO of Asymmetrex, James L. Sherley, M.D., Ph.D., explains, "Stem cell medicine has needed a quality and effectiveness index like drug specific activity for pharmaceuticals. What could work better than knowing the number of live tissue stem cells that can restore other tissue cells? That's what our KSC counting TORTOISE TestTM platform can tell doctors: the number of live stem cells in a treatment that can renew an organ or tissue."

Asymmetrex is currently focused on conducting preclinical and clinical evaluations of how well its tissue stem cell-specific data indicate the effectiveness of stem cell treatments in different patients. In his company's presentations at ISSCR 2021, Sherley says that he will also introduce the immediate benefits of KSC counting to stem cell scientists for their tissue stem cell research. "It's a no brainer that now knowing how many tissue stem cells are in experiments will greatly improve stem cell researchand, as a consequence, stem cell medicine."

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA (ARMI) and the Massachusetts Biotechnology Council (MassBio).

Media Contact: James L Sherley, jsherley@asymmetrex.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/asymmetrex-will-present-a-new-test-for-therapeutic-stem-cell-potency-at-the-isscr-2021-annual-meeting-301311815.html

SOURCE Asymmetrex, LLC

See original here:
Asymmetrex Will Present a New Test for Therapeutic Stem Cell Potency at the ISSCR 2021 Annual Meeting - BioSpace

Data Bridge Market Research has recently added a concise research on theGlobal Stem Cell Manufacturing Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market leaders while highlighting their competitive setting and corporate strategies for the estimated timeline. The development plans, market risks, opportunities and development threats are explained in detail. The CAGR value, technological development, new product launches and Industry competitive structure is elaborated. As per study key players of this market are Thermo Fisher Scientific. Merck Group, Becton, Dickinson and Company. Holostem Advanced Therapies, JCR Pharmaceuticals, Organogenesis Inc and more.

The Global Stem Cell manufacturing Market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 18.59 billion by 2027 growing at a CAGR of 6.42% in the above-mentioned forecast period. The growing awareness towards diseases like cancer, hematopoietic disorders and degenerative disorders is going to drive the growth of the stem cell manufacturing market.

Download FREE PDF sample copy of this research report@ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-artificial-intelligence-market

Global Stem Cell Manufacturing Market, By Product (Stem Cell Line, Instruments, Culture Media, Consumables), Application (Research Applications, Clinical Applications, Cell and Tissue Banking), End Users (Hospitals and Surgical Centers, Pharmaceutical and Biotechnology Companies, Clinics, Community Healthcare, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2027

Healthcare Infrastructure growth Installed base and New Technology Penetration

Stem cell manufacturing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for stem cell manufacturing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the stem cell manufacturing market. The data is available for historic period 2010 to 2018.

The Global Stem Cell Manufacturing Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of stem cell manufacturing market for global, Europe, North America, Asia Pacific and South America.

Global Stem Cell Manufacturing Market Scope and Market Size

Stem cell manufacturing market is segmented on the basis of product, application and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Major Market competitors/players:Global Stem Cell manufacturing Market

Some of the major players operating in the stem cell manufacturing market are Thermo Fisher Scientific. Merck Group, Becton, Dickinson and Company. Holostem Advanced Therapies, JCR Pharmaceuticals, Organogenesis Inc, Osiris Therapeutics, Osiris Therapeutics, Vericel Corporation, AbbVie, American CryoStem, AM-Pharma, Anterogen.Co.,Ltd, Astellas Pharma, Bristol-Myers Squibb, Apceth Biopharma, Cellular Dynamics International, Rheacell, Takeda Pharmaceutical, Teva Pharmaceutical Industries Ltd. ViaCyte, VistaGen Therapeutics Inc, Translational Biosciences, GlaxoSmithKline plc, Daiichi Sankyo Company, Limited, among others.

Market Definition:

This market report defines the market trends and forecast the upcoming opportunities and threats of the stem cell manufacturing market in the next 8 years. Stem cell manufacturing is a process of extracting the cells either from bone marrow or peripheral blood cells and culturing the cells in the culture dish containing nutrient media. Stem cells can be isolated from umbilical cord blood, placenta, amniotic sac, amniotic fluid, adipose tissue and menstrual blood. Stem cell manufacturing is used in the cell therapy as well as in gene therapy. Stem cell therapy is under research for many diseases like degenerative diseases and hematopoietic disorders like sickle cell anemia, storage disorders. Now stem cells are also used in making the cell and tissue bank. Some of the cell culture banks are National Institute of Biomedical Innovation, Health and Nutrition and World Federation for Culture Collections.

Key Insights in the report:

Inquire about this report from our experts @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-stem-cell-manufacturing-market

Opportunities in the market

Major Market Drivers:

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: sopan.gedam@databridgemarketresearch.com

Read the rest here:
Stem Cell manufacturing Market All-Inclusive Research Report (20212027) : Includes Impact of COVID-19 The Manomet Current - The Manomet Current

Dublin, June 18, 2021 (GLOBE NEWSWIRE) -- The "Global Cell Isolation Market By Product (Consumables and Instruments), By Cell Type (Human Cells and Animal Cells), By Source, By Technique, By Application, By End-User, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

The Global Cell Isolation Market was valued at USD7013.71 million in 2020 and is anticipated to reach USD15529.45 million by 2026 by registering a CAGR of 15.25% until 2026.

Cell isolation is a technique of isolating cells for diagnosis and analysis of a particular type of cell. The market growth can be attributed to the rising demand for drugs, vaccines and other related products, as they are manufactured with the assistance of cell isolation technique. Increasing popularity of precision medicines is also working in the favor of the market growth.

The Global Cell Isolation Market has been segmented into product, cell type, source, technique, application, end-user, company and region. Based on technique, the market is further fragmented into centrifugation-based cell isolation, surface-marker based cell isolation and filtration-based cell isolation, amongst which, centrifugation-based cell isolation segment occupied the largest market share in 2020 as it finds extensive applications in various end-user sectors such as academic institutes, research laboratories, etc.

Based on application, the market is further divided into biomolecule isolation, cancer research, stem cell research, in vitro diagnostics and others. Among these, cancer research and stem cell research are projected to be the lucrative segments of the market in the forecast period. Increase in the research activities by biopharma companies and laboratory is the key factor for the growth of the segments.

Based on regional analysis, Asia-Pacific is expected to grow at the highest CAGR during the forecast period. The high CAGR of the region can be attributed to the relaxation in the stringent rules and regulations laid down by the government for drug development. Another factor that can be held responsible for the fastest growth of the region is the availability of competent researchers and personnel who can carry out cell isolation techniques along with a wide genome pool.

The market players are focusing on research and development activities in order to enhance their product portfolios and strengthen their position across the global market. For instance, the major pharmaceutical companies worldwide are making substantial investments in R&D to introduce new drugs in the market.

Such investments are expected to increase the demand for cell isolation products over the coming years. In addition to this, new product developments help vendors to expand their product portfolio and gain maximum share in the sector. For example, Thermo Scientific's Medifuge is a benchtop centrifuge which is having a unique hybrid rotor as well as an interchangeable swing-out buckets and fixed-angle rotors to facilitate rapid & convenient applications on a single platform.

Moreover, collaborations, mergers & acquisitions and regional expansions are some of the other strategic initiatives taken by major companies for serving the unmet needs of their customers.

Major players operating in the Global Cell Isolation Market include

Years considered for this report:

Objective of the Study:

Key Target Audience:

Report Scope:

Global Cell Isolation Market, By Product:

Global Cell Isolation Market, By Cell Type:

Global Cell Isolation Market, By Source:

Global Cell Isolation Market, By Technique:

Global Cell Isolation Market, By Application:

Global Cell Isolation Market, By End-User:

Global Cell Isolation Market, By Region:

Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/r/osam26

Read more from the original source:
Global $15.52 Bn Cell Isolation (Human Cells and Animal Cells) - GlobeNewswire

A team of researchers at the RIKEN Center for Biosystems Dynamics Research in Kobe, Japan, may have just found an answer to hair loss and baldness woes. While many methods have been devised in the past to address hair-related issues, this one is unique, for its a recipe for continuous cyclical regeneration of hair follicles from hair follicle stem cells. At RIKENs, a team led by Takashi Tsuji had been working on methods to regenerate lost hair from stem cells. As part of their experiment, the researchers took fur and whisker cells from mice and processed them in controlled conditions with other biological ingredients in a laboratory.

In apress release, they said that 220 combinations of ingredients were used and it was discovered that combining a type of collagen with five factors the NFFSE medium led to the highest rate of stem cell amplification in the shortest time. The researchers further explained that hair growth among mammals is a continuous cyclical process. The hair grows, falls out, and grows again. While the growth occurs in the anagen phase, hair falls out in the telogen phase. And therefore, they said a hair-regeneration treatment is successful only when it produces hair that recycles. In their experiment, they placed bio-engineered hair follicle stem cells in NFFSE medium and observed the regenerated hair for several weeks.

The study demonstrated that 81 percent of hair follicles generated in the NFFSE medium went through at least three hair cycles and produced normal hair. In contrast, 79 percent of follicles grown in the other medium produced only one hair cycle, they said.

Besides, the researchers also looked for markers on the surface of the cell cultured in the NFFSE medium and found that the best hair cycling was related to the addition of Itg5. Makoto Takeo, the first author of the study, said that they discovered almost 80 percent of follicles reached three hair cycles when Itg5 was also bioengineered into the hair follicle germ. However, only 13 percent reached three cycles when it was not present.

Tsuji said that RIKENs culture system will help make hair follicle regeneration therapy a reality in the near future. RIKEN is primarily an institute that does basic research, explained Tsuji. And clinical trials usually require outside collaborators. We are therefore looking for a partner company to help develop the clinical applications and welcome donations to promote the R&D.

Also read: Tripura HC observes disparity in distribution of vaccines among districts

Continued here:
Tired of hair loss? New studies have solutions for hair loss or baldness - EastMojo

June 4, 2021

John Theurer Cancer Center investigators report new findings at American Society of Clinical Oncology 2021 Annual Meeting

Researchers from Hackensack University Medical Centers John Theurer Cancer Center, a part of Georgetown Lombardi Comprehensive Cancer Center, are presenting data from 25 studies at the Annual Meeting of the American Society of Clinical Oncology, the largest gathering of cancer professionals in the country. This years meeting is being held virtually June 4-8, 2021. Abstracts of the studies can be viewed at abstracts.asco.org.

At John Theurer Cancer Center patients have access to the latest cancer treatments and technologies, including those being evaluated in clinical trials. People with all types and stages of cancer are treated by world-renown experts. The cancer center is especially well-known for its research that drives treatment guidelines, and expertise in the management of hematologic cancers, having pioneered more effective therapies for leukemia, lymphoma, and multiple myeloma. John Theurer Cancer Center was the first center in New Jersey to offer CAR T-cell therapy, a revolutionary immunotherapy for patients with select leukemias and lymphomas. The center is home to one of the nations largest bone marrow transplant programs, with more than 7,500 completed.

Many of the studies being presented at ASCO report on novel treatments for patients with recurrent or persistent multiple myeloma or non-Hodgkin lymphomas (including mantle cell lymphoma, an especially challenging type), as well as acute myeloid leukemia and chronic lymphocytic leukemia. John Theurer Cancer Center investigators are also leaders in the development of immunotherapy regimens, and several of the studies being presented at ASCO evaluated its effectiveness and side effects, including real-world data in unique patient populations. Other studies report provocative findings on targeted therapies and other treatments for kidney and bladder cancers, brain cancer, and other solid tumors. Data from the following studies by John Theurer Cancer Center researchers are being presented at ASCOs 2021 virtual meeting:

Blood Cancers and Stem Cell Transplantation

Developmental Therapeutics and Immunotherapy

Targeted Therapies and Tumor Biology

Central Nervous System Tumors

The COVID-19 pandemic challenged health care in ways we have never been challenged before. Despitethe obstacles it presented, however, investigators at John Theurer Cancer Center continued to expand our understanding of cancer, refine its treatment, and develop innovative approaches to improve patient outcomes,"asserted Andre Goy, M.D., M.S., chairman and executive director of John Theurer Cancer Center.

Visit link:
Innovative research refines the treatment of patients with advanced cancers and the use of immunotherapy - Network News, Press Releases - Hackensack...

SAN DIEGOandSTOCKHOLM, Sweden, June 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento")today announced that the Company has entered into an additional collaborative agreement with NextGenNK Competence Center-associated research groups at the Department of Medicine, Huddinge, KarolinskaInstitutet(KI) inStockholm, Sweden, aimed at producing novelcell-based therapeutics using natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs). Sorrento and KI are collaborative partners in the Competence Center for the development of next-generation NK cell-based cancer immunotherapies (NextGenNK) coordinated by KI.

Under the agreement, Sorrento willprovide know-how in the core chimeric antigen receptor (CAR) and dimeric antigen receptor (DAR) technologies and support the collaborative effort to develop newCAR-NK andDAR-NK candidates, as well as fund the translational validation of the technologies. Multiple product candidates will be developed and tested in the initial phase of the planned work, with the goal that the candidate products will qualify for further human clinical trials.

The foundational Sorrento research assets critical to this program are novel proprietary CAR and DARconstructsidentified through Sorrentos proprietary G-MAB fully human antibody library and previously validated as determinants of cell-based therapy potency against hematologic and solid tumors.

It is a privilege to continue and extend ourcollaborative workwith the distinguished KI faculty. We are proud to contribute our technologiesto producenewoptimizedoff-the-shelf adoptive NK cell immunotherapies," said Dr.Henry Ji, Chairman and CEO of Sorrento. "Our partnership with KIcombines our know-how with the expertise of aworld-renownedinstitution in thefield ofNK cell therapy.Thesetypes ofpartnershipsareessential inadvancing medicine and bringingnew solutionstocancerpatients inneed.

KI scientists within NextGenNK will establishiPSC-derived NK-basedtherapeutic candidatesutilizing Sorrentos constructs and DAR technology. Work within KI has contributed to the development of methodologies that consistently generate robust and potent NK cell lineages following iPSC differentiation. Clinical trials of NK cell-based therapies for treatment of multiple myeloma led by researchers at KI have yielded promising preliminary results with long-lasting remissions. In a very cross-knit collaboration between Sorrento and KI, the team will aim to establish novel allogeneic, off-the-shelf, retargeted NK cell-based therapies.

Utilizing iPSCs enables mass production of off-the-shelf NK cell therapies that leverage Sorrentos existing manufacturing infrastructure and know-how. Sorrento expects these validated re-engineered NK cell-based therapeutic candidates could potentially become a new generation in off-the-shelf treatments for cancer and infectious diseases. Thecoreresearch will be performed atKarolinskaInstitutet withactiveinvolvement oftheSorrento R&Dteamin San Diego.

The present collaboration brings together key competence from Sorrento and KI in an important area of cancer immunotherapy research. Sorrentos intellectual contribution to the research at the Competence Center is a critical piece in enabling retargeted off-the-shelf NK cell products, said Evren Alici, Principal Investigator at KI.

This is an important step in further enabling academic and industrial partnerships in the mission of achieving common goals for advancement of novel cancer immunotherapies, said Hans-Gustaf Ljunggren, Director of the NextGenNK Competence Center.

About Sorrento Therapeutics, Inc.

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), clinical stage immuno-cellular therapies (CAR-T, DAR-T), antibody-drug conjugates (ADCs), and clinical stage oncolytic virus (Seprehvir). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIGUARD, COVI-AMG, COVISHIELD, Gene-MAb, COVI-MSC and COVIDROPS; and diagnostic test solutions, including COVITRACK, COVISTIX and COVITRACE.

Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule,resiniferatoxin(RTX), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercializeZTlido (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica.ZTlido was approved by the FDA on February 28, 2018.

For more information, visit http://www.sorrentotherapeutics.com.

About KarolinskaInstitutet

Karolinska Institutet is one of the worlds leading medical universities. Our vision is to advance knowledge about life and strive towards better health for all. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the countrys broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.

For more information about KarolinskaInstitutet, visit https://ki.se/en/research/research-at-karolinska-institutet.

For more information about NextGenNK, visit https://ki.se/en/research/nextgennk.

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding Sorrentos and KIs to bring off-the-shelf NK cell-based cancer treatments to patients; Sorrentos and KIs ability to produce novel cell-based therapeutics using NK cells derived from iPSCs; Sorrentos and KIs ability to develop new CAR-NK and DAR-NK candidates and to validate such technologies; the expectation that the collaborative effort will result in the development and testing of multiple product candidates and that any such product candidates will qualify for human clinical trials; the ability of KI scientists to establish iPSC-derived NK-based therapeutic candidates utilizing Sorrentos constructs and DAR technology; the expectation that utilizing iPSCs will enable mass production of off-the-shelf NK cell therapies; the potential for Sorrento to be able to use its existing manufacturing infrastructure and know-how to mass produce any off-the-shelf NK cell therapies; the potential for re-engineered NK cell-based therapeutic candidates to become a new generation in off-the-shelf treatments for cancer and infectious diseases; and the therapeutic potential of iPSC-derived NK-based therapeutic candidates. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries, affiliates and partners technologies and prospects and collaborations with partners, including, but not limited to: risks related to seeking regulatory approvals; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test, study and trial results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist Sorrento in the execution of its therapeutic antibody product candidate strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2020, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Media and Investor Relations ContactAlexis Nahama, DVM (SVP Corporate Development)Email: mediarelations@sorrentotherapeutics.com

Sorrento and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

G-MAB, DAR-T, SOFUSA, COVIGUARD, COVI-AMG, COVISHIELD, Gene-MAb, COVIDROPS, COVI-MSC, COVITRACK, COVITRACE and COVISTIX are trademarks of Sorrento Therapeutics, Inc.

SEMDEXA is a trademark of Semnur Pharmaceuticals, Inc.

ZTlido is a registered trademark owned by Scilex Pharmaceuticals Inc.

All other trademarks are the property of their respective owners.

2021 Sorrento Therapeutics, Inc. All Rights Reserved.

Continued here:
Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric - GlobeNewswire

The global stem therapy market growth will be driven by extensive R&D activities aimed at developing novel therapies and personalized medicines. For example, to treat patients who have suffered a myocardial infarction (heart attack), scientists are emphasizing on developing techniques to regenerate healthy heart from placental stem cells.

As per the Centers for Disease Control and Prevention (CDC), heart diseases in the U.S. cause nearly 655,000 deaths each year. The development of novel therapies will aid in treating patients suffering from cardiovascular disease more effectively and reducing mortality rates. Ongoing examination of the different aspects of stem cell therapy by researchers to explore its application in neurological disorders can help in the treatment of complex diseases.

According to a Global Market Insights, Inc., report, stem cell therapy market size will surpass US$15 billion by 2025.

Described below are some key factors driving the stem cell therapy market trends.

Higher risk of degenerative diseases among the elderly

The substantial rise in the geriatric population and increasing chronic ailments would boost the demand for stem cell therapies. Older people happen to be more vulnerable to degenerative diseases such as Alzheimers and Parkinsons disorders. As compared to traditional therapeutic methods, the various benefits of stem cell therapy can make it preferable for the treatment of degenerative diseases. Newer solutions are based on minimally invasive techniques that generate healthy cells by replacing the defectives cells in the host.

Use of allogenic stem cell therapy in leukemia treatment

Allogenic transplant is used to completely replace host cells with the donor cells. It also possesses the potential to eliminate viral reservoirs and genetic alterations in host cells. Because of these capabilities, allogenic stem cell therapy is used for treating patients suffering from leukemia and other chronic disorders.

Reportedly, the annual valuation of allogenic stem cell therapy market was estimated to be worth US$3 billion in 2018 and it will grow substantially in the forthcoming years.

To access sample pages of this report titled, Stem Cell Therapy Market Size By Type (Allogenic Stem Cell Therapy, Autologous Stem Cell Therapy), By Application (Oncology, Orthopedic, Cardiovascular, Neurology), End-users (Hospitals, Clinics) Industry Analysis Report, Regional Outlook, Technology Potential, Competitive Market Share & Forecast, 2019 - 2025 in detail along with the table of contents, please click on the link below:

https://www.gminsights.com/request-sample/detail/3331

Global increase in trauma cases and bone-joint injuries

Rising incidences of accidents and trauma cases across the globe will augment demand for orthopedic care solutions. Stem cell therapy has a high success rate in the treatment of bone-joint injuries such as ligament tendon, osteogenesis imperfecta, femoral head, spinal, and fractured bone defects.

Additionally, the growing preference for mesenchymal stem cell therapy in nursing orthopedic diseases such as osteoporosis and arthritis can be attributed to its ability differentiate bones and cartilage Notably, the share of orthopedic application segment of stem cell therapy is estimated to rise at a significant CAGR of 9% up to 2025.

Availability of advanced stem cell therapies in clinical settings

The availability of technologically advanced medical equipment and highly skilled professionals in clinical facilities enable the delivery of safe and superior quality stem cell therapies. Clinics can provide specialized stem cell treatment for a wide range of applications including orthopedics, oncology, and cardiovascular disorders. Reportedly, clinics accounted for more than 35% revenue share of stem cell therapy market in 2018.

Increasing burden of chronic diseases in Europe

Europes stem cell therapy market is projected to experience a CAGR of nearly 10% up to 2025. The escalating prevalence of various chronic diseases will drive the demand for advanced therapeutic solutions in the region. Ongoing efforts from regulatory bodies to create awareness regarding stem cell therapy and its advantages among people will bolster the regional industry outlook.

The presence of stringent regulations pertaining to the quality control of these therapies could affect its adoption rate slightly. However, their high success rate in the treatment of complex diseases will fuel global stem cell therapy market expansion in near future.

Prominent firms involved in the development of novel stem cell therapy solutions include Takeda Pharmaceuticals, ReNeuron Group, Celyad, Capricor Therapeutics, Gamida Cell, Novadip Biosciences, Cellular Dynamics, DiscGenics, CESCA Therapeutics, Mesoblast, OxStem, Cellectis, and Astellas Pharma. These companies are focusing on several strategies such as acquisitions, mergers, and new product development to sustain their market position.

About Global Market Insights, Inc.

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.

Contact Us:

Arun HegdeCorporate Sales, USAGlobal Market Insights, Inc.Phone:1-302-846-7766Toll Free:1-888-689-0688Email:sales@gminsights.comWebsite:https://www.gminsights.com

See original here:
Stem Cell Therapy Market: Top 5 trends fueling the industry revenue through 2025 - BioSpace

USC Stem Cell scientist Ya-Wen Chen hopes to pioneer a new approach to regenerating damaged lung tissue, with support from a Catalyst Grant from the American Lung Association (ALA). The award provides $50,000 year for up to two years.

For many patients with chronic lung diseases, the only available treatment is transplantationa difficult, dangerous surgery that involves challenges ranging from the severe shortage of donor organs to immune rejection, said Chen, who is an assistant professor of medicine, and stem cell biology and regenerative medicine at USC. Even patients who are lucky enough to receive donor organs only have a 10 to 20 percent survival rate at 10 years. If we can encourage these patients own cells to repair damage and heal their lungs, we could dramatically improve this prognosis.

With this goal in mind, Chen is using human stem cells to generate rudimentary lung-like structures known as lung bud organoids. Within these organoids, Chens group will probe how a specific population of cells repairs the tiny gas-exchange interfaces called alveoli in damaged lungs.

Specifically, Chen is interested in a population of cells known as distal small airway epithelial progenitors or SAEPs, which could have the potential to improve lung function in patients with idiopathic pulmonary fibrosis (IPF) or chronic obstructive pulmonary disease (COPD). A group of lung diseases that includes chronic bronchitis and emphysema, COPD affects at least 16 million Americans and is the third leading cause of death in the U.S. An additional 200,000 Americans are living with IPF, a progressive, incurable and often deadly disease that, for unknown reasons, causes scar tissue to form in the lungs, impeding breathing.

Our ultimate goal is to leverage patients existing stem and progenitor cells to promote healing through a non-surgical, regenerative approach, said Chen, a member of the USC Hastings Center for Pulmonary Research, as well as USCs stem cell research center.

Chen is one of 98 scientists to receive research support from the ALA, which has committed $11.55 million total to support scientific investigations aimed at reducing the burden of lung disease.

Despite the fact that the pandemic poses significant economic challenges, said ALA President and CEO Harold Wimmer, the American Lung Association is prioritizing research and significantly increasing award funding to help improve the lung health of all Americans.

Read more here:
USC scientist Ya-Wen Chen receives American Lung Association grant to advance stem cell-based lung therapies - USC News

Recently, Creative Bioarray announced the release of its stem cell line generation services in order to promote scientific research.

New York, USA - February 9, 2021 - Creative Bioarray, the world's leading biotechnology company focuses on offering high quality products and services including cell services, biosample services and histology services to accelerate life science research, help scientists solve complex analytical issues. Recently, Creative Bioarray announced the release of its stem cell line generation services in order to promote scientific research.

At present, stem cell research and application are focused on adult stem cells and iPSC, which is a technology called "reprogramming" to develop stem cells from somatic cells. Therefore, generating stem cell lines from different sources through different methods to maintain the high purity and viability of stem cells is extremely important in stem cell research. Creative Bioarray is committed to providing detailed data and comprehensive services for scientific research.

Adult stem cells provide a platform for different disease research or drug selection. The most common use of adult stem cells is MSC, which has basic functions in cell therapy, immunomodulation and gene therapy. Creative Bioarray can provide customers with stable and purified MSC lines and other adult stem cell lines in a short period of time to meet customer needs.

iPSC technology is a promising breakthrough in regenerative medicine. It was first proposed by Yamanaka in 2006. By reprogramming somatic cells such as fibroblasts and blood cells, iPSCs can be directly generated. Creative Bioarray provides customers with iPSC strains with high viability, which can be produced from different cell sources by globally recognized methods.

Creative Bioarray's advantages for stem cell lines generation services mainly include globally recognized advanced methods, stable and pure cell lines from reliable sources, service quality assurance, and detailed reports of experimental results.

"Creative Bioarray is an experienced and outstanding provider of stem cell research services. We are committed to providing detailed data and comprehensive services for your scientific research, and we are happy to use our rich experience and advanced platform to provide the best services to meet every customer's needs," said Hannah Cole, the marketing director of Creative Bioarray.

About Creative Bioarray

Founded in 2005, Creative Bioarray is dedicated to offering customers with innovative biotechnology products and services for research use to greatly enhance and drive innovation and standards in science. As a well-recognized industry leader with more than 10 years of experience and in-house experts supported, Creative Bioarray has already countenanced research all around the world.

Media ContactCompany Name: Creative BioarrayContact Person: Hannah ColeEmail: Send EmailPhone: 1-631-619-7922Country: United StatesWebsite: https://www.creative-bioarray.com

Original post:
Creative Bioarray Offers Stem Cell Lines Generation Service for Promoting Scientific Research - Press Release - Digital Journal

In older adult patients undergoing nonmyeloablative allogeneic hematopoietic cell transplantation (HCT), treatment with JSP191 combined with low dose total body irradiation (TBI) and fludarabine appears safe, well-tolerated treatment option capable of clearing minimal residual disease (MRD)positivity, according to a poster presented during the 2021 Transplantation and Cellular Therapy Meetings.

While the results of this phase 1 trial (NCT04429191) are early, the investigators emphasized that these data are the first to demonstrate that the antiCD117 monoclonal antibody is safe and effective in this disease cohort.

We are developing a first-in-class monoclonal antibody (mAb), JSP191, which targets and depletes normal and MDS/AML disease-initiating hematopoietic stem cells, wrote the investigators. JSP191 acts by inhibiting stem cell factor binding to CD117 present on HSC. We and others showed in pre-clinical models that HSC depletion can be enhanced by combining anti-CD117 mAb with low dose total body radiation.

The anti-CD117 monoclonal antibody was administered to a total of 6 patients intravenously at a dose of 0.6 mg/kg. Of note, the study population consisted of patients aged 60 years or older with MRD detected via cytogenetics, difference from normal flow cytometry, or next-generation sequencing (NGS).

The dual primary end points of the study are the safety and tolerability of JSP191 combined with low dose total body radiation and fludarabine and of JSP191 pharmacokinetics. The secondary end points include engraftment and donor chimerism, MRD clearance, event-free survival, and overall survival, among others.

The team used serum concentration of JSP191 determined by pharmacokinetics to establish the predicted JSP191 clearance and safety for the administration of fludarabine at 30 mg/m2 per day for 3 days, at days 4, -3, and -2 leading up to transplant.

At 28 days following transplant, 5 out of 6 patients showed signs of complete (>95%) donor CD15 myeloid chimerism in the peripheral blood.

To this point, there has been no evidence of significant infusion toxicities or JSP191-related serious adverse events. Also, a reduction or elimination of MRD in all subjects was seen at 28 days following transplant.

The research team explained that blood stem cell transplantation may offer the only curative therapy for many forms of both AML and MDS. Even though the current standard-of-care conditioning regimens administered before blood stem cell transplantation are well tolerated, they remain associated with increased relapse rates due to the prevalence of disease-causing hematopoietic stem cells and inadequate graft versus leukemia effect.

Further accrual for this study continues, while correlative analyses focusing on JPS191s impact with disease-initiating hematopoietic stem cells are ongoing.

References:

Muffly L, Kwon HS, Chin M, et al. Phase 1 study of JSP191, an anti-CD117 monoclonal antibody, with low dose irradiation and fludarabine in older adults with MRD-positive AML/MDS undergoing allogeneic HCT. Presented at the 2021 Transplantation and Cellular Therapy Meetings, held February 8-12, 2021. Abstract LBA5.

Link:
JSP191 With Low Dose Irradiation and Chemotherpy Demonstrates Efficacy and Safety in MRD+ AML/MDS - Targeted Oncology